Response

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
² Department of Research and Development, Korean Institute of Tuberculosis, Osong, South Korea.
³ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: yimjj@snu.ac.kr.

Comment

Nakwon Kwak et al. Chest. 2021 Jul.

. 2021 Jul;160(1):e91.

doi: 10.1016/j.chest.2021.02.058.

¹ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
² Department of Research and Development, Korean Institute of Tuberculosis, Osong, South Korea.
³ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: yimjj@snu.ac.kr.

No abstract available

Comment on

Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome.
Kwak N, Whang J, Yang JS, Kim TS, Kim SA, Yim JJ. Kwak N, et al. Chest. 2021 Feb;159(2):517-523. doi: 10.1016/j.chest.2020.07.040. Epub 2020 Jul 24. Chest. 2021. PMID: 32712225
Clofazimine Drug Susceptibility Testing for Nontuberculous Mycobacteria: A Call to Arms.
Aksamit TR, Marras TK. Aksamit TR, et al. Chest. 2021 Jul;160(1):e90. doi: 10.1016/j.chest.2021.02.059. Chest. 2021. PMID: 34246401 No abstract available.